Hiki N, Berger D, Prigl C, Boelke E, Wiedeck H, Seidelmann M, Staib L, Kaminishi M, Oohara T, Beger H G
Department of General Surgery, University of Ulm, Germany.
Infect Immun. 1998 Mar;66(3):1135-41. doi: 10.1128/IAI.66.3.1135-1141.1998.
Little is known about the role of peripheral blood mononuclear cells (PBMCs) in lipopolysaccharide (LPS) elimination. We studied the endotoxin elimination capacities (EEC) of PBMCs of 15 healthy volunteers, 13 patients with sepsis, and 1 patient suffering from paroxysmal nocturnal hemoglobinuria (PNH). Although expression of CD14, the best-characterized receptor for LPS to date, was reduced from 93.6% +/- 0.8% in healthy subjects to 50.5% +/- 6.5% in patients with sepsis and was 0.3% in a patient with septic PNH, EEC were found to be unchanged. There was no difference in the amount of tumor necrosis factor alpha (TNF-alpha) released by PBMCs of healthy donors and patients with sepsis. Anti-CD14 antibodies (MEM-18) completely suppressed EEC, binding of fluorescein isothiocyanate-labeled LPS to monocytes as determined by FACScan analysis, and TNF-alpha release in all three groups studied. The concentrations of soluble CD14 (sCD14) secreted by endotoxin-stimulated PBMCs from healthy donors and patients with sepsis amounted to 4.5 +/- 0.4 and 20.1 +/- 1.8 ng/ml, respectively. Based on our results, we suggest that PBMCs eliminate LPS by at least two different mechanisms; in healthy subjects, the membrane CD14 (mCD14) receptor is the most important factor for LPS elimination, while in patients with sepsis (including the septic state of PNH), increased sCD14 participates in LPS elimination. Secretion of sCD14 is strongly enhanced under conditions of low expression of mCD14 in order to counteract the reduction of mCD14 and maintain the function of monocytes. This sCD14 may substitute the role of mCD14 in LPS elimination during sepsis. The elimination of LPS by PBMCs correlates with the binding reaction and the secretion of TNF-alpha.
关于外周血单个核细胞(PBMCs)在脂多糖(LPS)清除中的作用,人们了解甚少。我们研究了15名健康志愿者、13名脓毒症患者和1名阵发性夜间血红蛋白尿(PNH)患者的PBMCs的内毒素清除能力(EEC)。尽管迄今为止LPS特征最明确的受体CD14的表达,在健康受试者中从93.6%±0.8%降至脓毒症患者的50.5%±6.5%,而在脓毒症PNH患者中为0.3%,但EEC并未改变。健康供体和脓毒症患者的PBMCs释放的肿瘤坏死因子α(TNF-α)量没有差异。抗CD14抗体(MEM-18)完全抑制了所研究的所有三组的EEC、通过流式细胞仪分析测定的异硫氰酸荧光素标记的LPS与单核细胞的结合以及TNF-α释放。内毒素刺激的健康供体和脓毒症患者的PBMCs分泌的可溶性CD14(sCD14)浓度分别为4.5±0.4和20.1±1.8 ng/ml。基于我们的结果,我们认为PBMCs通过至少两种不同机制清除LPS;在健康受试者中,膜CD14(mCD14)受体是LPS清除的最重要因素;而在脓毒症患者(包括PNH的脓毒症状态)中,sCD14增加参与LPS清除。在mCD14低表达的情况下,sCD14的分泌会强烈增强,以抵消mCD14的减少并维持单核细胞的功能。这种sCD14可能在脓毒症期间替代mCD14在LPS清除中的作用。PBMCs对LPS的清除与结合反应以及TNF-α的分泌相关。